Mdd Us Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MDD US, and what generic alternatives to MDD US drugs are available?
MDD US has two approved drugs.
There are three US patents protecting MDD US drugs.
There are eighty patent family members on MDD US drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.
Summary for Mdd Us
| International Patents: | 80 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Mdd Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,283,380 | See Plans and Pricing | See Plans and Pricing | ||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,076,515 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,278,485 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Mdd Us | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-002 | Apr 20, 2004 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,278,485 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mdd Us Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009541232 | See Plans and Pricing |
| European Patent Office | 2029524 | See Plans and Pricing |
| Mexico | 2008015704 | See Plans and Pricing |
| Japan | 2006522800 | See Plans and Pricing |
| European Patent Office | 2474521 | See Plans and Pricing |
| South Korea | 101410291 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mdd Us Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613296 | 122015000058 | Germany | See Plans and Pricing | PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 1613296 | 300752 | Netherlands | See Plans and Pricing | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 1613296 | 241 50017-2015 | Slovakia | See Plans and Pricing | PRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226 |
| 1613296 | 92782 | Luxembourg | See Plans and Pricing | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| 1613296 | 15C0054 | France | See Plans and Pricing | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 1613296 | C 2015 034 | Romania | See Plans and Pricing | PRODUCT NAME: SAFINAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/14/984; DATE OF NATIONAL AUTHORISATION: 20150224; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/984; DATE OF FIRST AUTHORISATION IN EEA: 20150224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
